Autolus Therapeutics (AUTL) Registration filing summary

Company overview and business model

• Early commercial-stage biopharmaceutical company focused on next-generation T cell therapies for cancer and autoimmune diseases.

• Lead product AUCATZYL (obe-cel) approved by FDA in November 2024 for adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL); commercial launch in US in January 2025.

• AUCATZYL also received conditional marketing authorization in the UK and EU, with UK launch in January 2026; EU launch on hold for 2026.

• Pipeline includes expansion of obe-cel into pediatric B-ALL, B-NHL, autoimmune diseases (lupus, multiple sclerosis), and other oncology indications.

• Proprietary T cell programming technologies aim to improve targeting, control, and tolerability of therapies.

Financial performance and metrics

• ADSs listed on Nasdaq under symbol "AUTL"; closing price on April 9, 2026 was $1.47.

• 320,727,536 ordinary shares outstanding after offering, based on December 31, 2025 figures.

Use of proceeds and capital allocation

• No proceeds to the company from the resale of ADSs by selling securityholders; company will receive proceeds only from warrant exercises.

• Company bears registration costs; selling securityholders bear underwriting fees, commissions, and certain legal expenses.